射血分数保留的心力衰竭:从机制到治疗
本综述从转化医学视角阐述射血分数保留的心力衰竭(HFpEF),将其定义为心脏无法满足机体循环需求或需依赖左室充盈压升高来满足需求的血流动力学状态。作者提出淤血发生的「最终共同通路」——左室舒张末压升高、左房高压、肺静脉淤血和血浆容量扩张——是HFpEF治疗的重要初始靶点,并围绕六种机制(三种血流动力学机制与三种分子机制)探讨潜在疗法。
要点
- HFpEF是血流动力学疾病,核心是心脏无法满足循环需求或需升高左室充盈压代偿。
- 淤血的最终共同通路包括左室舒张末压升高、左房高压、肺静脉淤血和血浆容量扩张。
- 治疗靶点可分三种血流动力学机制与三种分子机制,后者包括微血管炎症、代谢异常和结构异常。
核心结论
- HFpEF应被视为一种血流动力学状态,其淤血的最终共同通路是治疗的重要初始靶点。
研究设计与样本
- 本文为综述,从转化医学视角将HFpEF的机制进展与潜在疗法相联系。
主要发现
- HFpEF被定义为心脏无法满足机体循环需求或需以升高左室充盈压为代价来满足需求的血流动力学状态。
关键数值与推荐
- 淤血的最终共同通路包括左室舒张末压升高、左房高压、肺静脉淤血和血浆容量扩张。
- 治疗靶点分为三种血流动力学机制:左房高压、肺动脉高压和血浆容量扩张。
- 治疗靶点还包括三种分子机制:全身微血管炎症、心血管代谢功能异常和细胞(肌联蛋白)/细胞外(纤维化)结构异常。
临床怎么用
- 临床可围绕淤血的最终共同通路(左室舒张末压升高、左房高压、肺静脉淤血、血浆容量扩张)考虑HFpEF的初始治疗靶点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This review aims to provide a translational perspective on recent developments in heart failure with preserved ejection fraction (HFpEF), linking mechanistic insights to potential therapies. A key concept in this review is that HFpEF is a haemodynamic condition wherein the heart fails to keep up with the circulatory demands of the body, or does so at the expense of raised left ventricular filling pressures. We, therefore, propose that the 'final common pathway' for development of congestion, i.e. basic haemodynamic mechanisms of increased left ventricular end-diastolic pressure, left atrial hypertension, pulmonary venous congestion, and plasma volume expansion, represents important initial targets for therapy in HFpEF. Accordingly, we group this review into six mechanisms translating into potential therapies for HFpEF: beginning with three haemodynamic mechanisms (left atrial hypertension, pulmonary hypertension, and plasma volume expansion), and working backward to three potential molecular mechanisms [systemic microvascular inflammation, cardiometabolic functional abnormalities, and cellular (titin)/extracellular (fibrosis) structural abnormalities].
引用
- Lam CSP, Voors AA, de Boer RA, et al. Heart failure with preserved ejection fraction: from mechanisms to therapies. Eur Heart J. 2018. PMID: 29905796. doi:10.1093/eurheartj/ehy301
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。